GOP Senators Press FDA On Puberty Blocker Risks After Vanderbilt Transgender Clinic

“[T]he off-label use of GnRH agonists in connection with diagnoses of gender dysphoria or the provision of transgender care is, by definition, intended to suppress the normal biological processes of puberty beyond the normal age of onset.

Given that such off-label use deliberately delays and alters normal development, We are deeply concerned that it could result in significant short-term and long-term risks and adverse effects on adolescent patients,” the senators wrote.